The diagnosis and treatment of giant cell arteritis

Deutsches Arzteblatt International

Volumn 110, Issue 21, 2013, Pages 376-384

  Ness, Thomas ^a   Bley, Thorsten A ^b   Schmidt, Wolfgang A ^c   Lamprecht, Peter ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CORTICOSTEROID; FERRITIN ANTIBODY; METHOTREXATE;

ANTERIOR ISCHEMIC OPTIC NEUROPATHY; AORTA ANEURYSM; AORTA STENOSIS; ARTERY STEAL SYNDROME; ARTICLE; BLINDNESS; BLOOD VESSEL BIOPSY; BRAIN ISCHEMIA; CENTRAL RETINA VEIN OCCLUSION; CLINICAL EXAMINATION; COLOR CODED DUPLEX SONOGRAPHY; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DRUG CONTRAINDICATION; DYSPHAGIA; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; GERMANY; GIANT CELL ARTERITIS; HEADACHE; HUMAN; INFLAMMATION; INTRAOCULAR HYPOTENSION; ISCHEMIC OPTIC NEUROPATHY; LEUKOCYTOSIS; META ANALYSIS (TOPIC); MYALGIA; NECROSIS; NORMOCHROMIC NORMOCYTIC ANEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR ISCHEMIC SYNDROME; ODYNOPHAGIA; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RHEUMATIC POLYMYALGIA; SKIN DISEASE; THROMBOCYTOSIS; VISUAL DISORDER; WEIGHT REDUCTION;

EID: 84906329099     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0376     Document Type: Article

References (40)

1. Horton BT, Magath TB, Brown GE: An undescribed form of arteritis of the temporal vessels. Proc Mayo Clin 1932; 7: 700-1
2. Jennette JC, Falk RJ, Andrassy K, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92
3. Vaith P, Warnatz K: Clinical and serological findings of giant-cell arteritis. Z Rheumatol 2009; 68: 124-31
4. Blockmans D: The use of (18F)fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis. Clin Exp Rheumatol 2009; 21: 15-22
5. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL: Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3532-7
6. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48: 3522-31
7. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL: Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2012 Dec 19. [Epub ahead of print]
8. Vaith P, Bley T: Primär systemische Vaskulitiden-große Gefäße. In: Peter HH, Pichler WJ, Müleer-Ladner (eds): Klinische Immunologie. 3rd edition. München: Urban & Fischer 2012; 363-9
9. Salvarani C, Cantini F, Boiardi L, Hunder GG: Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-71
10. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al.: 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-92
11. Ness T, Auw-Hadrich C, Schmidt D: Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment. Ophthalmologe 2006; 103: 296-301
12. Kale N, Eggenberger E: Diagnosis and management of giant cell arteritis: a review. Curr Opin Ophthalmol 2010; 21: 417-22
13. Kermani TA, Schmidt J, Crowson CS, et al.: Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012; 41: 866-71
14. Hunder GG, Bloch DA, Michel BA, et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8
15. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al.: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine 2005; 84: 277-90
16. Ciccarelli M, Jeanmonod D, Jeanmonod R: Giant cell temporal arteritis with a normal erythrocyte sedimentation rate: report of a case. Am J Emerg Med 2009; 27: 255: e1-3
17. Parikh M, Miller NR, Lee AG, et al.: Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006; 113: 1842-5
18. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-42
19. Bley TA, Uhl M, Carew J, et al.: Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol 2007; 28: 1722-7
20. Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M: High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005; 184: 283-7
21. Bley TA, Wieben O, Vaith P, Schmidt D, Ghanem NA, Langer M: Magnetic resonance imaging depicts mural inflammation of the temporal artery in giant cell arteritis. Arthritis Rheum 2004; 51: 1062-1063; author reply 1064
22. Hauenstein C, Reinhard M, Geiger J, et al.: Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology 2012; 51: 1999-03
23. Poller DN, van Wyk Q, Jeffrey MJ: The importance of skip lesions in temporal arteritis. J Clin Pathol 2000; 53: 137-9
24. Zhou L, Luneau K, Weyand CM, Biousse V, Newman NJ, Grossniklaus HE: Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases. Ophthalmology 2009; 116: 1574-80
25. Ji J, Liu X, Sundquist K, Sundquist J, Hemminki K: Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 2010; 49: 1158-63
26. Kermani TA, Schafer VS, Crowson CS, et al.: Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res 2010; 62: 149-54
27. Mukhtyar C, Guillevin L, Cid MC: EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-23
28. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8
29. Mazlumzadeh M, Hunder GG, Easley KA, et al.: Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310-8
30. Chevalet P, Barrier JH, Pottier P, et al.: A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000; 27: 1484-91
31. Hayreh SS, Zimmerman B: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204-15
32. Wipfler-Freissmuth E, Loock J, Moosig F, Dejaco C, Duftner C, Schirmer M: Current therapeutic options for giant cell arteritis. Z Rheumatol 2009; 68: 132-6
33. Mahr AD, Jover JA, Spiera RF, et al.: Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-97
34. De Silva M, Hazleman BL: Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-8
35. Hoffman GS, Cid MC, Rendt-Zagar KE, et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30
36. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67: 625-30
37. Lee MS, Smith SD, Galor A, Hoffman GS: Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306-9
38. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M: Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-7
39. Ness T, Schmidt D: Arteriitis temporalis: Temporalarterienbiopsie, Anamnese und Blutwerte. Zeitschrift für praktische Augenheilkunde 2005; 26: 327-32
40. Dasgupta B, Borg FA, Hassan N, et al.: BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010; 49: 1594-7.